Teva Pharmaceutical Industries Limited
TEVJF
$37.00
$8.6030.28%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.32B | 17.35B | 17.26B | 16.78B | 16.63B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.32B | 17.35B | 17.26B | 16.78B | 16.63B |
| Cost of Revenue | 8.23B | 8.32B | 8.32B | 8.37B | 8.38B |
| Gross Profit | 9.08B | 9.03B | 8.94B | 8.40B | 8.25B |
| SG&A Expenses | 4.13B | 4.05B | 3.97B | 3.80B | 3.75B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -40.00M | -17.00M | -1.00M | 21.00M | 14.00M |
| Total Operating Expenses | 14.03B | 13.34B | 13.30B | 13.19B | 13.13B |
| Operating Income | 3.28B | 4.01B | 3.95B | 3.59B | 3.50B |
| Income Before Tax | 719.00M | 1.38B | 1.24B | 899.00M | -70.00M |
| Income Tax Expenses | 12.00M | -187.00M | -180.00M | 238.00M | 93.00M |
| Earnings from Continuing Operations | 707.00 | 1.57K | 1.42K | 661.00 | -163.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.00M | -1.00M | -7.00M | 51.00M | 5.00M |
| Net Income | 706.00M | 1.56B | 1.41B | 712.00M | -158.00M |
| EBIT | 3.28B | 4.01B | 3.95B | 3.59B | 3.50B |
| EBITDA | 4.27B | 5.01B | 4.96B | 4.60B | 4.53B |
| EPS Basic | 0.62 | 1.36 | 1.23 | 0.62 | -0.14 |
| Normalized Basic EPS | 1.30 | 1.68 | 1.65 | 1.50 | 1.40 |
| EPS Diluted | 0.59 | 1.33 | 1.20 | 0.60 | -0.16 |
| Normalized Diluted EPS | 1.28 | 1.65 | 1.62 | 1.48 | 1.39 |
| Average Basic Shares Outstanding | 4.62B | 4.60B | 4.58B | 4.57B | 4.55B |
| Average Diluted Shares Outstanding | 4.68B | 4.68B | 4.66B | 4.62B | 4.59B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |